Trial Outcomes & Findings for Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes (NCT NCT04899778)

NCT ID: NCT04899778

Last Updated: 2025-05-01

Results Overview

Any injury resulting in time away from practice or competition

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

73 participants

Primary outcome timeframe

over the course of 1 year

Results posted on

2025-05-01

Participant Flow

Participant milestones

Participant milestones
Measure
Oral Contraceptive Pill
Oral contraceptive, 1/day, for one year Oral Contraceptive Pill or IUC with hormones
No Oral Contraceptive
No intervention
Overall Study
STARTED
31
42
Overall Study
COMPLETED
31
42
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
OCs Users
n=31 Participants
Participant athletes regularly took oral contraceptives or had a hormone-containing IUD.
Non-OCs
n=42 Participants
Participant athletes were not on any form of contraception.
Total
n=73 Participants
Total of all reporting groups
Age, Categorical
<=18 years
1 Participants
n=31 Participants
2 Participants
n=42 Participants
3 Participants
n=73 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
n=31 Participants
40 Participants
n=42 Participants
70 Participants
n=73 Participants
Age, Categorical
>=65 years
0 Participants
n=31 Participants
0 Participants
n=42 Participants
0 Participants
n=73 Participants
Age, Continuous
21.3 years
STANDARD_DEVIATION 3.3 • n=31 Participants
21.9 years
STANDARD_DEVIATION 3.7 • n=42 Participants
21.6 years
STANDARD_DEVIATION 3.5 • n=73 Participants
Sex: Female, Male
Female
31 Participants
n=31 Participants
42 Participants
n=42 Participants
73 Participants
n=73 Participants
Sex: Female, Male
Male
0 Participants
n=31 Participants
0 Participants
n=42 Participants
0 Participants
n=73 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.

PRIMARY outcome

Timeframe: over the course of 1 year

Population: collegiate and professional female athletes

Any injury resulting in time away from practice or competition

Outcome measures

Outcome measures
Measure
Oral Contraceptive Pill
n=31 Participants
Oral contraceptive, 1/day, for one year Oral Contraceptive Pill or IUC with hormones
No Oral Contraceptive
n=42 Participants
No intervention
Injury
8 Participants
16 Participants

SECONDARY outcome

Timeframe: baseline, 4 month visit

level of relaxin measured in each subject

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline, 4 month visit

Anterior Knee laxity will be evaluated using the KT-2000 and measured in millimeters of anterior translation of the tibia relative to the femur

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline, 4 month visit

Hip flexion, adduction, and internal/external and coronal plane rotation of the knee measured during a singled-legged drop using motion tracking equipment.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline, 4 month visit

Hip flexion, adduction, and internal/external and coronal plane rotation of the knee measured during a singled-legged drop using motion tracking equipment.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: baseline, 4 month visit

Beighton score will be used to assess overall joint laxity. The Beighton score is on a nine-point scale that is based on 5 joint maneuvers. The maximum score is 9, which indicates increased laxity in the joints. A score of zero indicates inflexible joints.

Outcome measures

Outcome data not reported

Adverse Events

Oral Contraceptive Pill

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

No Oral Contraceptive

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Melodie Metzger

Cedars-Sinai Medical Center

Phone: 310-423-7765

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place